NDUFB11
ENSG00000147123
Target class
Enzyme
Chromosome
X
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB11
- Gene name
- NADH:ubiquinone oxidoreductase subunit B11
- Gene symbol
- NDUFB11
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial (Complex I-ESSS) (CI-ESSS) (NADH-ubiquinone oxidoreductase ESSS subunit) (Neuronal protein 17.3) (Np17.3) (p17.3)
- ESSS
- NP17.3
- Np15
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 325.44
- Tissue specificity (Gini)
- 0.146
- Tissue specificity (tau)
- 0.513
- KEGG gene identifiers
- hsa:54539
- Protein interaction confidence
- 0.94
- Protein interaction partners
- 91
- R-HSA-611105
- R-HSA-6799198
- End position
- 47145466
- Start position
- 47142071
- Chromosome
- X
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein . Note=The interaction with BCAP31 mediates mitochondria localization. .
- Acrosome
- Connecting piece
- Equatorial segment
- Mid piece
- Mitochondria
- Principal piece
- PubMed 31206022
- PubMed 12611891
- Tissue specificity (tau)
- 0.513431
- Expression inequality (Gini)
- 0.145558
Expression in transcripts per million
- Muscle - Skeletal
- 325.44
- Thyroid
- 275.26
- Pituitary
- 235.7
- Adrenal Gland
- 230.54
- Cells - EBV-transformed lymphocytes
- 219.9
Expression in transcripts per million
- Muscle - Skeletal325.44
- Thyroid275.26
- Pituitary235.7
- Adrenal Gland230.54
- Cells - EBV-transformed lymphocytes219.9
- Heart - Left Ventricle215.02
- Cells - Cultured fibroblasts211.24
- Kidney - Medulla199.75
- Heart - Atrial Appendage194.77
- Colon - Sigmoid191.31
- Prostate187.65
- Cervix - Ectocervix183.5
- Cervix - Endocervix181.11
- Artery - Aorta181.1
- Brain - Cerebellar Hemisphere180.36
- Esophagus - Mucosa177.24
- Artery - Coronary170.13
- Vagina169.91
- Brain - Cerebellum168.94
- Spleen168.25
- Esophagus - Gastroesophageal Junction166.74
- Brain - Frontal Cortex (BA9)165.66
- Stomach165.21
- Fallopian Tube164.46
- Artery - Tibial163.44
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor